FATE News and Press, Fate Therapeutics Inc. From 08/08/21

Using the quarterly 13F filings we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion Assets Under Management. After the Q1-2021 13F filings the consensus holdings are updated, 5 stocks were removed and 6 added from the universe now holds 48 s...

Image source: The Motley Fool. Fate Therapeutics, inc (NASDAQ: FATE) Q2 2021 Earnings Call Aug 6, 2021 , 8:00 p.m. ET Operator Continue reading For further details see: Fate Therapeutics, inc (FATE) Q2 2021 Earnings Call Transcript

Fate Therapeutics, Inc. (FATE) Q2 2021 Earnings Conference Call August 04, 2021, 05:00 PM ET Company Participants Scott Wolchko - President and CEO Ed Dulac - CFO Conference Call Participants Yigal Nochomovitz - Citi Michael Schmidt - Guggenheim Alethia Young - Cantor Fitzgerald Michael Yee -...

First Patient Treated for Relapsed / Refractory ALL in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-cell Therapy; Off-the-Shelf Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus FT516...

SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced the appointment of Yuan Xu, Ph.D., to its Board of Directors as an ...

Fate Therapeutics (NASDAQ:FATE) announces that the first patient has been treated with FT819, an off-the-shelf chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies. The multi-center Phase 1 trial is designed to determine the recommended Phase 2 dose and schedule of...

Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus Phase 1 Clinical Study will Evaluate Three Dosing Regimens of FT819 for Patients with Advanced B-cell Leukemias and Lymphomas SAN DIEGO...

Using the quarterly 13F filings, we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion Assets Under Management. After the Q1-2021 13F filings, the consensus holdings are updated, 5 stocks were removed and 6 added from the universe; now holds 4...

Rock-star money manager Cathie Wood makes it easy for the rest of us to see what's in her shopping bag. She posts nightly buy and sell transaction reports across all of her ARK Invest exchange-traded funds, and it's always interesting to see which names are becoming a bigger part of her fir...

Biotech Penny Stocks & Small Caps Gain Ground After Cytokinetics Gets Boost On News When it comes to penny stocks or small-caps, in general, sector & industry trends can play a role. Broader markets and indexes like the S&P 500 ETF ( NYSE: SPY ) and Nasdaq ETF ( NASDAQ...